Dealings involving intentional release

Commercial supply of multivalent cat vaccines containing a genetically modified component for the prevention of feline leukemia virus infection

Commercial release of tomato genetically modified for purple fruit colour

Commercial supply of nadofaragene firadenovec for bladder cancer treatment

Commercial release of cotton genetically modified for insect resistance and herbicide tolerance (Bollgard® 3 ThryvOn™ cotton with XtendFlex® Technology)

Limited and controlled release of canola genetically modified for dairy protein production

Trial of a genetically modified (GM) vaccine for the prevention of respiratory disease in horses.

Clinical trial of a genetically modified human adenovirus for the treatment of melanoma

Limited and controlled release of canola genetically modified for increased photosynthesis and photorespiration

Limited and controlled release of safflower genetically modified for dairy protein production and altered fat composition

Clinical trials of controlled infection with seasonal Influenza viruses

Limited and controlled release of sorghum genetically modified for altered reproduction from sexual to asexual

Clinical trial of GM vaccinia virus for the treatment of solid tumours

Commercial release of a genetically modified (GM) mosquito strain to help prevent dengue outbreaks

Clinical trial for the treatment of mycobacterial infections using bacteriophages

Limited and controlled release of canola genetically modified for increased abiotic stress tolerance.

Limited and controlled release of wheat genetically modified for increased tolerance to environmental stress

Limited and controlled release of cotton genetically modified for herbicide tolerance and insect resistance

Commercial supply of a live attenuated vaccine containing canine distemper virus and a genetically modified canine parvovirus (Nobivac Puppy DP Plus) for dogs

Limited and controlled release of wheat and barley genetically modified for yield enhancement

Fermentation and processing of recombinant proteins using genetically modified Pichia pastoris

Commercial release of banana genetically modified for resistance to Fusarium wilt tropical race 4 (TR4)

Clinical trial of a genetically modified alphavirus (Getah virus) for cancer treatment

Clinical trial of genetically modified Lactobacillus brevis for treatment of inflammatory bowel disease

Commercial supply of Qdenga, a live attenuated GM dengue vaccine

Trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils

Limited and controlled release of perennial ryegrass genetically modified for increased metabolisable energy content

Commercial supply of a genetically modified vaccine against infectious laryngotracheitis virus in chickens

Clinical trial of a genetically modified (GM) chimeric Orthopoxvirus (CF33-hNIS) as a cancer treatment

Commercial import and distribution of chrysanthemum genetically modified for altered flower colour

Commercial release of Indian mustard genetically modified for herbicide tolerance (RF3)

Limited and controlled release of sorghum genetically modified for asexual seed formation

Limited and controlled release of canola and Indian mustard genetically modified for altered oil content and herbicide tolerance

Clinical trial of a genetically modified alphavirus for treatment of cancer

Limited and controlled release of wheat and barley genetically modified for yield enhancement and improved abiotic stress tolerance

Clinical trial with a genetically modified Bordetella pertussis for the prevention of whooping cough

Clinical trial with a genetically modified human adenovirus COVID-19 vaccine

Clinical trial with genetically modified E.coli to reduce antibiotic resistance

Commercial supply of a genetically modified COVID-19 vaccine

Clinical trial of a genetically modified Herpes virus for the treatment of cystic fibrosis

Commercial supply of a genetically modified COVID-19 vaccine

Clinical trial with a genetically modified Vaccinia virus based treatment for solid cancerous tumours

Commercial release of canola genetically modified for herbicide tolerance and a hybrid breeding system (MS11× RF3 and MS11 × RF3 × MON 88302)

Clinical trial of genetically modified human adenovirus for bladder cancer treatment

Limited and controlled release of white clover genetically modified for increased condensed tannins

Commercial release of canola (Brassica napus) genetically modified for herbicide tolerance and a hybrid breeding system (MS11)

Commercial supply of a genetically modified cholera vaccine, Vaxchora®

Commercial release of cotton genetically modified for herbicide tolerance (MON 88701)

Clinical trial of genetically modified influenza vaccine (H3N2 M2SR)

Trial of genetically modified vaccines against Ross River virus infection in horses